SOAT1 and inflammatory skin disease: JAK inhibitors exert their therapeutic effect by blocking the JAK-STAT signaling pathway, which mediates the activity of multiple proinflammatory cytokines implicated in the pathogenesis of inflammatory skin disorders [5].